LAVENDER Trial Enrollment Complete

LAVENDER Trial Enrollment Complete

302589

LAVENDER Trial Enrollment Complete

Acadia Pharmaceuticals has completed enrollment in the Phase 3 clinical trial LAVENDER, which is testing the investigational medication trofinetide as a treatment for Rett syndrome. Top-line results from the study are expected later this year, according to a press release. LAVENDER (NCT04181723) enrolled approximately 180 female Rett syndrome patients ages 5 to 20. Participants are assigned randomly to either trofinetide or a placebo, given twice daily for 12 weeks. As primary goals, the trial will…

You must be logged in to read/download the full post.